Cme Group Inc. CME
Revenue Intelligence Report • 70 quarters of SEC filing data • Updated 2026-03-15
Revenue is driven by efficient SG&A spend, with every $1 of SG&A generating $2.53 of long-run revenue, indicating strong cost leverage underpinning topline growth. The model is linear and well-validated, with a 5.8% MAPE and a holdout test that predicted $1.6B versus actual $1.6B (0.5% error). Latest quarterly revenue was $1.649B, and the FY forecast is $6.9B, up 6.4% year over year. The ongoing SG&A ROI supports a constructive outlook with stable, mid-single-digit top-line growth and durable revenue expansion.
Investment Thesis
The econometric model achieves strong accuracy (5.8% MAPE), suggesting Cme Group Inc.'s revenue trajectory is well-characterized by its spending patterns. Each $1 of SG&A spending generates $2.53 in revenue, reflecting strong commercial efficiency.
Revenue Forecast
Quarterly Detail
| Quarter | Model Forecast | Actual | 95% Range | YoY Growth | Status |
|---|---|---|---|---|---|
| Q4 2025 | $1.6B | $1.6B | $1.5B – $1.8B | +7.5% | ✓ In range |
| Q2 2026 | $1.8B | $1.5B – $2.0B | +6.7% | ||
| Q3 2026 | $1.7B | $1.4B – $2.0B | +1.7% | ||
| Q4 2026 | $1.7B | $1.4B – $2.0B | +10.4% | ||
| Q1 2027 | $1.8B | $1.4B – $2.1B | +7.4% |
How Spending Drives Revenue
Want this analysis for your portfolio?
I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.
Get in Touch